Proteomics International funds its commercial leap with discounted SPP

Discounted SPP targets A$5 million

Proteomics International Laboratories Ltd (ASX:PIQ) is asking eligible Australian and New Zealand shareholders for up to A$5 million to finance its next commercial phase, offering new shares at A$0.10 each. The price represents a 12.2% discount to the five-day VWAP of A$0.1139 and a 16.7% discount to the A$0.12 closing price on 30 October.

Participation is capped at A$30,000 per shareholder and is optional. The offer is not underwritten, meaning the final amount raised is not guaranteed; Proteomics can accept oversubscriptions, close early or scale back applications.

Commercial rollout is the funding case

The raise arrives as the company shifts its emphasis from scientific development to execution. Proteomics says it has secured a national Healius distribution partnership and commenced the Australian rollout of PromarkerD and PromarkerEso, following the national Healius rollout reported in late October.

It is also targeting the launch of PromarkerEndo between January and March 2027. The planned use of funds includes commercial execution and market access, laboratory operations and capacity, clinical evidence generation, reimbursement activities, product launches and preparations for entry into the United States. The company also cites a US market pathway alongside its three clinically validated tests, while the earlier US PromarkerEndo patent had strengthened its intellectual property position.

Free options add value and dilution risk

Subject to shareholder approval, each share issued under the SPP will carry one free option. The options would be exercisable at A$0.15 and expire two years after issue, but they will not be issued if shareholders reject the required resolution at the 20 November annual meeting. Any options ultimately exercised would add to the company's share count and bring in additional capital at the exercise price.

Proteomics presents an indicative funding pool of A$9.1 million, comprising A$1.8 million in opening cash, A$2 million from the research and development tax incentive, A$0.3 million of other income and the intended A$5 million SPP proceeds. Planned expenditure includes A$2.5 million for corporate costs and working capital, A$2 million for research and product development, and A$1.6 million each for clinical and regulatory work and commercial execution. The board can vary those allocations, and the timetable remains subject to change.

The immediate test is participation: how much shareholders commit, whether the offer is scaled back and whether the option package wins approval. The more consequential test comes after the raise, when Healius distribution, PromarkerEndo's planned launch and the company's reimbursement and US preparation work must convert a larger funding base into measurable commercial progress.